New study reveals promising results for Helicobacter pylori eradication with Lacidofil

Published: 2-Nov-2023

A new study highlights the potential of Lacidofil as an adjuvant to standard therapy as an effective approach for Helicobacter pylori eradication.

“Backed by more than 29 positive clinical trials with more than 1000 participants and preclinical scientific evidence, Lacidofil has consistently demonstrated its beneficial effects on maintaining a healthy intestinal microbiota, leading to overall well-being." 

"This new study strengthens the evidence already available showing that Lacidofil is an effective adjuvant to standard therapy for H. pylori eradication and reduces the side-effects of the antibiotics in this therapy,” confirms Marie-Laure Oula, Clinical Program Manager at Lallemand Health Solutions.

This new double-blind, randomised, placebo-controlled study shows the efficacy and safety of Lacidofil — a unique formula combining two proprietary probiotic bacteria strains L. rhamnosus Rosell-11 and L. helveticus Rosell-52.

The study included 90 adults, taking either a placebo or Lacidofil with standard triple therapy for 2 weeks and then continued with either the placebo or the probiotic alone for 4 additional weeks.

Gastrointestinal comfort and general health-related quality of life criteria were analysed at baseline, and after 2 and 6 weeks of probiotic intervention.

New study reveals promising results for Helicobacter pylori eradication with Lacidofil

The analyses showed a statistically significant decrease of gastrointestinal discomfort and increase of general health-related quality of life at week 6 compared with the placebo group (p<0.001 and p=0.02, respectively).

The study also highlights that Lacidofil is able to increase the eradication rate of H. pylori (p=0.047).

Lacidofil has been on the market since 1995 and is now available in more than 20 countries, both as a standalone product and as an ingredient in combination with other strains.

With a proven record of safe use and a robust pharmacovigilance programme, Lacidofil has earned strong Canadian claims approval for various health applications, including promoting healthy microflora in infants as young as 2 months old, such as 

  • addressing Antibiotic-Associated Diarrhoea (AAD)
  • managing acute diarrhoea
  • supporting GI balance during Helicobacter pylori eradication therapy
  • offering specific benefits for pregnant women.

Offered in various galenic forms, including powders, capsules and drops, Lacidofil is a versatile probiotic solution meeting market demand.

You may also like